Playing Doctor: The Impact of the Tysabri Risk Plan

The market resurrection of Tysabri demonstrates the power of risk management but raises a tough question: how far can FDA and industry go into the practice of medicine? Biogen Idec declare they are nt trying to tell doctors how to practice. The strict rules of the risk management plan suggest otherwise.

More from Archive

More from Pink Sheet